-
1 Comment
Chengdu Kanghong Pharmaceuticals Group Co., Ltd is currently in a long term downtrend where the price is trading 37.3% below its 200 day moving average.
From a valuation standpoint, the stock is 20.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 7.7.
Chengdu Kanghong Pharmaceuticals Group Co., Ltd's total revenue rose by 12.6% to $955M since the same quarter in the previous year.
Its net income has increased by 47.3% to $244M since the same quarter in the previous year.
Finally, its free cash flow grew by 1952.3% to $395M since the same quarter in the previous year.
Based on the above factors, Chengdu Kanghong Pharmaceuticals Group Co., Ltd gets an overall score of 4/5.
| ISIN | CNE1000020C4 |
|---|---|
| Industry | Drug Manufacturers-Specialty & Generic |
| CurrencyCode | CNY |
| Exchange | SHE |
| Sector | Healthcare |
| PE Ratio | 33.93 |
|---|---|
| Dividend Yield | 0.5% |
| Target Price | 24 |
| Market Cap | 18B |
| Beta | 0.03 |
Chengdu Kanghong Pharmaceuticals Group Co., Ltd engages in the research, development, production, and sale of biological products, Chinese medicines, and chemical drugs in China. It offers ophthalmic systems, central nervous systems, digestive systems, and other system drugs. The company was founded in 1996 and is headquartered in Chengdu, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 002773.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
